BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

...are J.P. Morgan, BofA Securities and Cowen. Nurix’s are J.P. Morgan, Piper Sandler, Stifel and Needham...
BioCentury | Jun 3, 2020
Finance

Third Rock-launched Pliant is latest biotech to climb on public debut

...and Applied Molecular Transport Inc. (see “IPO Queue Grows” ). Citigroup, Cowen, Piper Sandler and Needham...
...deal. Targets CD51 (CD29) - Integrin α(V)β(1) Danielle Kopke, Staff Writer PLN-1474 PLN-74809 Pliant Therapeutics Inc. Novartis AG Third Rock Ventures Citigroup Cowen Piper Sandler Needham Integrin...
BioCentury | May 25, 2020
Finance

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

...successors from Pfizer Inc. (NYSE:PFE). Its underwriters are BofA Securities, Jefferies, Evercore ISI, Cantor and Needham...
BioCentury | May 11, 2020
Finance

Third Rock-backed fibrosis company Pliant joins IPO queue

...AbbVie Inc. (NYSE:ABBV), following its acquisition of Tobira Therapeutics Inc. Citigroup, Cowen, Piper Sandler and Needham...
BioCentury | Dec 5, 2019
Financial News

Follow-on Roundup: Arrowhead, Kodiak, Relmada, Revance

...Tuesday’s close of $20.15. The deal was underwritten by Cowen, Piper Jaffray, Stifel, Guggenheim, and Needham...
BioCentury | Oct 16, 2019
Financial News

Oct. 15 Financial Quick Takes: Phathom, Galera, J&J earnings, RTW Investments, Azitra, MaveriX

...million at a postmoney valuation of $491.8 million. Underwriters are Goldman Sachs, Jefferies, Evercore and Needham...
BioCentury | Oct 2, 2019
Financial News

Three new IPO filings broaden fall queue

...14.2% each and Takeda 9.1%. Underwriters on the deal are Goldman Sachs, Jefferies, Evercore and Needham...
BioCentury | Aug 14, 2019
Finance

Renovacor raises $11M to advance gene therapy for rare cardiomyopathy

...halt disease progression in the long term, Cook said. Renovacor also announced that Broadview’s Tom Needham...
...out how it works,” Jones said. Broadview, meanwhile, invests primarily in therapies for cardiovascular diseases. Needham...
BioCentury | Apr 4, 2019
Financial News

Follow-on roundup: Sangamo, Tricida, DBV

...after market hours to raise $222 million. Underwriters are Goldman Sachs, J.P. Morgan, Cowen and Needham...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...Biosciences Inc. (NYSE:RCUS), Hayward, Calif. Catapult Therapeutics B.V., Lelystad, the Netherlands Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham...
Items per page:
1 - 10 of 1343
BioCentury | Jul 24, 2020
Finance

Four more biotech IPOs reach the market, but no big first-day pop in the bunch

...are J.P. Morgan, BofA Securities and Cowen. Nurix’s are J.P. Morgan, Piper Sandler, Stifel and Needham...
BioCentury | Jun 3, 2020
Finance

Third Rock-launched Pliant is latest biotech to climb on public debut

...and Applied Molecular Transport Inc. (see “IPO Queue Grows” ). Citigroup, Cowen, Piper Sandler and Needham...
...deal. Targets CD51 (CD29) - Integrin α(V)β(1) Danielle Kopke, Staff Writer PLN-1474 PLN-74809 Pliant Therapeutics Inc. Novartis AG Third Rock Ventures Citigroup Cowen Piper Sandler Needham Integrin...
BioCentury | May 25, 2020
Finance

New additions to the IPO queue: Generation Bio, Avidity, Vaxcyte and more

...successors from Pfizer Inc. (NYSE:PFE). Its underwriters are BofA Securities, Jefferies, Evercore ISI, Cantor and Needham...
BioCentury | May 11, 2020
Finance

Third Rock-backed fibrosis company Pliant joins IPO queue

...AbbVie Inc. (NYSE:ABBV), following its acquisition of Tobira Therapeutics Inc. Citigroup, Cowen, Piper Sandler and Needham...
BioCentury | Dec 5, 2019
Financial News

Follow-on Roundup: Arrowhead, Kodiak, Relmada, Revance

...Tuesday’s close of $20.15. The deal was underwritten by Cowen, Piper Jaffray, Stifel, Guggenheim, and Needham...
BioCentury | Oct 16, 2019
Financial News

Oct. 15 Financial Quick Takes: Phathom, Galera, J&J earnings, RTW Investments, Azitra, MaveriX

...million at a postmoney valuation of $491.8 million. Underwriters are Goldman Sachs, Jefferies, Evercore and Needham...
BioCentury | Oct 2, 2019
Financial News

Three new IPO filings broaden fall queue

...14.2% each and Takeda 9.1%. Underwriters on the deal are Goldman Sachs, Jefferies, Evercore and Needham...
BioCentury | Aug 14, 2019
Finance

Renovacor raises $11M to advance gene therapy for rare cardiomyopathy

...halt disease progression in the long term, Cook said. Renovacor also announced that Broadview’s Tom Needham...
...out how it works,” Jones said. Broadview, meanwhile, invests primarily in therapies for cardiovascular diseases. Needham...
BioCentury | Apr 4, 2019
Financial News

Follow-on roundup: Sangamo, Tricida, DBV

...after market hours to raise $222 million. Underwriters are Goldman Sachs, J.P. Morgan, Cowen and Needham...
BioCentury | Mar 29, 2019
Targets & Mechanisms

Next-wave targets at AACR 2019 start filling the blanks in the tumor microenvironment

...Biosciences Inc. (NYSE:RCUS), Hayward, Calif. Catapult Therapeutics B.V., Lelystad, the Netherlands Celldex Therapeutics Inc. (NASDAQ:CLDX), Needham...
Items per page:
1 - 10 of 1343